OBJECTIVE: There is a lack of research on adverse event (AE) detection in oncology patients, despite the propensity for iatrogenic harm. Two common methods include voluntary safety reporting (VSR) and chart review tools, such as the Institute for Healthcare Improvement's Global Trigger Tool (GTT). Our objective was to compare frequency and type of AEs detected by a modified GTT compared with VSR for identifying AEs in oncology patients in a larger clinical trial. METHODS: Patients across 6 oncology units (from July 1, 2013, through May 29, 2015) were randomly selected. Retrospective chart reviews were conducted by a team of nurses and physicians to identify AEs using the GTT. The VSR system was queried by the department of quality and safety of the hospital. Adverse event frequencies, type, and harm code for both methods were compared. RESULTS: The modified GTT detected 0.90 AEs per patient (79 AEs in 88 patients; 95% [0.71-1.12] AEs per patient) that were predominantly medication AEs (53/79); more than half of the AEs caused harm to the patients (41/79, 52%), but only one quarter were preventable (21/79; 27%). The VSR detected 0.24 AEs per patient (21 AEs in 88 patients; 95% [0.15-0.37] AEs per patient), a large plurality of which were medication/intravenous related (8/21); more than half did not cause harm (70%). Only 2% of the AEs (2/100) were detected by both methods. CONCLUSIONS: Neither the modified GTT nor the VSR system alone is sufficient for detecting AEs in oncology patient populations. Further studies exploring methods such as automated AE detection from electronic health records and leveraging patient-reported AEs are needed.
OBJECTIVE: There is a lack of research on adverse event (AE) detection in oncology patients, despite the propensity for iatrogenic harm. Two common methods include voluntary safety reporting (VSR) and chart review tools, such as the Institute for Healthcare Improvement's Global Trigger Tool (GTT). Our objective was to compare frequency and type of AEs detected by a modified GTT compared with VSR for identifying AEs in oncology patients in a larger clinical trial. METHODS: Patients across 6 oncology units (from July 1, 2013, through May 29, 2015) were randomly selected. Retrospective chart reviews were conducted by a team of nurses and physicians to identify AEs using the GTT. The VSR system was queried by the department of quality and safety of the hospital. Adverse event frequencies, type, and harm code for both methods were compared. RESULTS: The modified GTT detected 0.90 AEs per patient (79 AEs in 88 patients; 95% [0.71-1.12] AEs per patient) that were predominantly medication AEs (53/79); more than half of the AEs caused harm to the patients (41/79, 52%), but only one quarter were preventable (21/79; 27%). The VSR detected 0.24 AEs per patient (21 AEs in 88 patients; 95% [0.15-0.37] AEs per patient), a large plurality of which were medication/intravenous related (8/21); more than half did not cause harm (70%). Only 2% of the AEs (2/100) were detected by both methods. CONCLUSIONS: Neither the modified GTT nor the VSR system alone is sufficient for detecting AEs in oncology patient populations. Further studies exploring methods such as automated AE detection from electronic health records and leveraging patient-reported AEs are needed.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Allison Lipitz-Snyderman; David Classen; David Pfister; Aileen Killen; Coral L Atoria; Elizabeth Fortier; Andrew S Epstein; Christopher Anderson; Saul N Weingart Journal: J Oncol Pract Date: 2017-01-17 Impact factor: 3.840
Authors: David C Stockwell; Eric Kirkendall; Stephen E Muething; Elizabeth Kloppenborg; Hima Vinodrao; Brian R Jacobs Journal: J Patient Saf Date: 2013-12 Impact factor: 2.844
Authors: Mary A Blegen; Thomas Vaughn; Ginette Pepper; Carol Vojir; Karen Stratton; Michal Boyd; Gail Armstrong Journal: Am J Med Qual Date: 2004 Mar-Apr Impact factor: 1.852
Authors: Patricia C Dykes; Ronen Rozenblum; Anuj Dalal; Anthony Massaro; Frank Chang; Marsha Clements; Sarah Collins; Jacques Donze; Maureen Fagan; Priscilla Gazarian; John Hanna; Lisa Lehmann; Kathleen Leone; Stuart Lipsitz; Kelly McNally; Conny Morrison; Lipika Samal; Eli Mlaver; Kumiko Schnock; Diana Stade; Deborah Williams; Catherine Yoon; David W Bates Journal: Crit Care Med Date: 2017-08 Impact factor: 9.296
Authors: Sarah A Collins; Brittany Couture; Ann DeBord Smith; Esteban Gershanik; Elizabeth Lilley; Frank Chang; Cathy Yoon; Stuart Lipsitz; Aziz Sheikh; James Benneyan; David W Bates Journal: J Patient Saf Date: 2020-06 Impact factor: 2.243